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ABSTRACT
Objectives Global survival studies have shown favourable 
development in colon and rectal cancers but few studies 
have considered extended periods or covered populations 
for which medical care is essentially free of charge.
Design We analysed colon and rectal cancer survival in 
Finland and Sweden over a 50- year period (1967–2016) 
using data from the Nordcan database. In addition to the 
standard 1- year and 5- year survival rates, we calculated 
the difference between these as a novel measure of how 
well survival was maintained between years 1 and 5.
Results Relative 1- year and 5- year survival rates have 
developed favourably without major shifts for men and 
women in both countries. For Finnish men, 1- year survival 
in colon cancer increased from 50% to 82%, and for rectal 
cancer from 62% to 85%. The Swedish survival was a 
few per cent unit better for 1- year survival but for 5- year 
survival the results were equal. Survival of female patients 
for both cancers was somewhat better than survival in 
men through 50 years. Overall the survival gains were 
higher in the early compared with the late follow- up 
periods, and were the smallest in the last 10 years. The 
difference between 1- year and 5- year survival in colon 
cancer was essentially unchanged over the 50- year period 
while in rectal cancer there was a large improvement.
Conclusions The gradual positive development in survival 
suggests a contribution by many small improvements 
rather than single breakthroughs. The improvement in 
5- year survival in colon cancer was almost entirely driven 
by improvement in 1- year survival while in rectal cancer 
the positive development extended to survival past year 
1, probably due to successful curative treatments. The 
current challenges are to reinvigorate the apparently 
stalled positive development and to extend them to old 
patients. For colon cancer, survival gains need to be 
extended past year 1 of diagnosis.
INTRODUCTION
Incidence and mortality are common 
measures describing the population burden 
of disease (cancer) and they convey informa-
tion on survival.1 Survival in many cancers 
has improved over the past years in the devel-
oped countries.2 Although the underlying 
data appear undisputed, the reasons for the 
favourable development have many inter-
pretations. One of the early success stories 
was Hodgkin lymphoma for which the gains 
were ascribed to the use of risk- adapted ther-
apies using intensive poly- chemotherapeutic 
regimens in combination with other modal-
ities.3 In childhood acute lymphoblastic 
leukaemia, the improvements were ascribed 
to treatment- related precise risk stratifica-
tion, early assessment of minimal residual 
disease and supportive care.4 Success in 
testicular cancer care was ascribed to a 
rational utilisation of combination chemo-
therapy, and the integration of care involving 
medical and surgical specialties resulting in 
cure rates of over 90%.5 The key role of clin-
ical randomised trials in selecting the optimal 
treatment is universally emphasised in 
enabling these success stories, but for many 
other cancers the ‘real world’ cure circum-
stances may be far from the selected patient 
populations and controlled treatment proto-
cols of the clinical trials. Many survival studies 
cover relatively short periods which do not 
allow assessment of the survival experience 
over decenniums, which would be important 
to understand the factors influencing the 
‘real world’ survival trends.2 6–8
Cancers of the colon and the rectum are 
the second in the global ranking of incident 
and fatal cases after lung cancer.9 10 These 
Summary box
What is already known about this subject?
 ► Although it is known that survival in colon and rectal 
cancers has increased the reasons are not well un-
derstood, as long- term trends in countries with free 
medical care have been lacking.
What are the new findings?
 ► The gradual positive development in survival over 
50 years suggests a contribution by small improve-
ments rather than single break- throughs. The im-
provement in 5- year survival in colon cancer was 
almost entirely driven by improvement in 1- year 
survival while in rectal cancer the positive develop-
ment extended to survival past year 1.
How might it impact on clinical practice in the 
foreseeable future?
 ► For colon cancer, patient care needs to be improved 
past year 1 of diagnosis. For rectal cancer, care of 
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cancers are often considered jointly as ‘colorectal cancer, 
CRC’ as colon and rectal cancers share many biological 
features and risk factors. Yet some authors point out that 
the two cancers differ in their embryological origin and 
metastatic patterns, in addition to many therapy- related 
factors.11 12 The diagnostic and therapeutic principles for 
colon and rectal cancer have changed over the years as 
detailed in online supplemental material. We will discuss 
these in terms of the survival experience in Finland 
and Sweden over a period of 50 years. For a ‘real world’ 
experience, these two countries are examples of prac-
tically free- of- charge medical care to the population at 
large. The reason for selecting these two countries, and 
for example not all of the 5 Nordic Countries, is that 
the authors have first- hand knowledge about Finland 
and Sweden. Moreover, the extensive earlier literature 
between the Nordic cancer registries points out to large 
similarities, whereby data volume might distract from the 
findings.13 Sweden (population 10.2 million in 2019) has 
been internationally an example of high- level medical 
care and prosperous economy since the World War 
Two. The gross national product (GNP) per capita was 
US$3460 in 1967 and it increased to US$54 370 in 2016; 
the healthcare share improved from 6.6% to 11.0% of 
GNP in the same period ( www. macrotrends. net). GNP 
of Finland (population 5.5 million in 2019) was US$2035 
in 1967 and it increased to US$43 784 in 2016, with the 
related healthcare share increasing from 5.7% to 9.4% 
( www. macrotrends. net). With analysis of the incidence/
mortality/survival patterns in the Nordcan database, we 
try to understand factors underlying the improvements in 
survival in colon and rectal cancers over a 50- year period. 
However, as there is even current literature on incidence 
and mortality on CRC from Finland and Sweden, we 
report these data only in the supplement, in support of 
the survival analyses.10 14
METHODS
The data used originate from the Nordcan database 
which is a compilation of data from the Nordic cancer 
registries as described.15 These registries are presented 
in detail by Pukkala et al.16 The database can now be 
accessed at International Agency for Cancer (IARC) 
website (https:// nordcan. iarc. fr/ en/ database# bloc2). 
The analyses were conducted interchangeably at the 
IARC and the Nordcan sites (https:// nordcan. iarc. fr/ 
en/ database# bloc2). The database combines rectal and 
anal cancers (in accordance with International Classifi-
cation of Diseases version 7, ICD-7). We have no way of 
removing anal cancers but they constitute a tiny portion 
of all rectal and anal patients; for example, in 2016, 
92.4% of these cancers were rectal cancers, 96.5% among 
men and 86.9% among women.
Coverage of cancers in the Finnish and Swedish cancer 
registries is generally considered high.16 The Swedish 
cancer registry does not consider cancers in death noti-
fications and some 4% cases may be missed because of 
this; an overall comparison of various health records 
showed that the coverage was over 90%.16 17 Compara-
bility of diagnostics of a 50- year period may be an issue. 
The Swedish cancer registry used ICD-7 from the start of 
registration in 1958. When new codes have been taken to 
use, all diagnoses are additionally recoded in the ICD-7 
system to maintain consistence.18 Finland uses a code 
conversion system to maintain consistency. In Finland 
and Sweden, the cause of death register is independent 
from cancer registration, and the smoothly declining 
mortality trends are another indication for consistency of 
diagnostics (online supplemental figure 1).
Data on the Finnish and Swedish patients were extracted 
from Nordcan where the follow- up was extended until 
death, emigration or loss of follow- up or to the end of 
2016. For incidence and mortality data, the starting date 
was the earliest available, 1953 for Finland, 1960 for the 
Swedish incidence and 1952 for the mortality data. For 
age standardisation, the world standard population was 
used. In Nordcan, the tool for incidence and mortality 
analysis by period (‘Time trends (Incidence/Mortality’) 
were selected for analysis. Survival data for relative survival 
were available from 1967 onwards and the analysis was 
based on the cohort survival method for the first nine 
5- year periods from 1964 to 2011, and a hybrid analysis 
combining period and cohort survival in the last period 
2012–2016, as detailed.19 20 The hybrid method includes 
cases from the penultimate 5- year period to allow for a 
5- year survival.21 Age groups 0–89 were considered, and 
for age- standardisation the International Cancer Survival 
Standard was used. The Finnish and Swedish life tables 
were used to calculate the expected survival. Period- 
specific survival analysis was executed with tool ‘Table by 
country and period’, and the results were compiled from 
the relevant analyses. For age group specific survival, no 
case numbers were available. We estimated significance 
of the survival difference for the youngest and oldest age 
groups by comparing to the 95% CIs of all individuals in 
the relevant period.
We calculated also a difference in survival per cent 
between year 1 and year 5 as a measure on how well 
survival is maintained between years 1 and 5. A small 
difference indicates high survival between years 1 and 
5 after diagnosis. This measure may be more concretely 
described by the complementary mortality, X=100%-sur-
vival %. Thus if 1- year mortality X is small (say 10% with 
90% survival), and 5- year mortality is also small (say 20% 
with 80% survival) then mortality is low and survival is 
favourable in the interval between 1 and 5 years.
In graphic presentation, smoothing of data in 3- year 
intervals were used.
RESULTS
The Nordcan database included 0.49 million male and 
0.48 million female cancers for Finland, and 1.01 million 
male and 0.94 million female cancers for Sweden, 
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2016 (online supplemental table 1). Finnish male colon 
cancers numbered 24 851 (median age at diagnosis 71 
years) compared with 31 347 female colon cancers (73 
years); the related numbers for Sweden were 73 467 (72 
years) and 78 586 (74 years). Rectal and anal cancers 
numbered 19 889 (69 years) among Finnish men and 
17 924 (72 years) among women; the Swedish numbers 
were 49 231 (71 years) and 38 581 (72 years).
Incidence and mortality rates in colon and rectal 
(and anal) cancers in Finnish and Swedish men and 
women are shown in online supplemental figure 1. For 
colon cancer, the trends were quite similar for men and 
women, higher incidence for Sweden compared with 
Finland, and continuously increasing; mortality was 
declining since about 1973. For male rectal cancer, the 
incidence rate was modestly increasing while for women 
it was stable after 1980. Mortality rate has been declining 
with an equal rate for Finland and Sweden.
Relative 1- year and 5- year survival rates for colon, 
CRC and rectal cancers for Finnish and Swedish men 
are shown in table 1. The male 1- year survival for colon 
cancer improved constantly, from 50% (1967–1971) to 
82% (2012–2016) for Finnish men and from 56% to 84% 
for Swedish men. In Finland, the 1- year survival in rectal 
cancer increased from 62% to 85%, compared for the 
increase from 63% to 87% in Sweden. The male 5- year 
survival in Finnish colon cancer increased from 32% in 
1967–1971 to 65% in 2012–206; the comparable increase 
in Sweden was from 36% to 64%. For Finnish rectal 
cancer the increase was from 28% to 64% compared with 
the Swedish one from 34% to 64%. Of note, not a single 
survival percentage was improved in Finland between the 
last two periods. The survival data are plotted in online 
supplemental figure 2 (A, 1- year survival and B, 5- year 
survival; the related 95% CIs are shown in table 1) illus-
trating the catch- up of colon cancer with rectal cancer 
in the 1 year survival and almost superimposable increase 
for colon and rectal cancer in both countries for the 
5- year survival. The both sets of graphs were curvilinear; 
however, the 5- year survival curves only weakly deviated 
from linearity.
In table 1, the stars between the periods indicate a 
significant increase in survival (ie, 95% CIs were non- 
overlapping). Because statistical significance depends on 
the sample size, it is instructive to look at the stars for 
CRC. More significant changes were found in the early 
period than later, and no single significant change took 
place between the two last periods.
Table 1 shows also the difference between 1- year and 
5- year survival in per cent units (% units). In Finland, the 
Figure 1 Age- specific 1- year relative survival for colon cancer in (A) Finnish and (B) Swedish men and 5- year survival in the 
same male populations (C, D). For A and B, all data points for the youngest and oldest age groups are outside the 95% CI limits 
of all colon cancer survival (cf. table 1); the exceptions are the Swedish youngest age group data points between 1992 and 
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difference in colon cancer was initially 18% units, then 
increasing to 20% units and declining to 17% units in 
the last period. For rectal cancer, the largest difference 
of 33% units was in the first period and it declined to 
21% units. For Sweden, most of the values were some-
what higher than those for Finland.
Table 2 shows the development in female colon, CRC 
and rectal cancers. The changes are consistent with the 
male improvement but at almost every period the female 
survival is a few % points above the male survival. The 
exception was the Swedish 1- year survival for colon 
cancer for which the final 84% was equal for men and 
women. The survival data are plotted in online supple-
mental figure 3 (A, 1- year survival and B, 5- year survival; 
the related 95% CIs are shown in table 2) illustrating the 
somewhat higher 1- year survival for rectal than colon 
cancer with a narrowing margin; the 5- year survival 
graphs are practically superimposable. Also the female 
graphs are curvilinear.
According to table 2, the difference between 1- year and 
5- year survival in Finland for colon cancer was initially 
18% units, then increasing to 21% units and declining to 
18% units in the last period. For rectal, the largest differ-
ence of 33% units was in the first period and it declined 
to 18% units. For Sweden, the differences between 1- year 
and 5- year survival in colon cancer resembled the Finnish 
values but for rectal cancer the final difference of 21% 
units was higher than that in Finland.
The periodic 1- year and 5- year survival rates for male 
and female colon and rectal cancers in online supple-
mental figure 4 illustrate the point about approximately 
similar differences between 1- year and 5- year survival for 
colon cancer and periodic narrowing of the differences 
for rectal cancer.
Age- specific 1- year relative survival for colon cancer in 
Finnish (figure 1A) and Swedish (figure 1B) men showed 
that young men survived well and only the oldest age 
group, 80–89 years, experienced markedly poorer survival 
that the younger ones but the gap narrowed with time. 
The 5- year survival was most favourable for patients diag-
nosed before age 50 years in Finland (C) while for the 
older patients survival was almost equal; in Sweden (D) 
there was hardly any difference between the age groups.
The age- specific survival for male rectal (and anal) cancer 
in Finland and in Sweden is shown in figure 2. The two 
oldest age groups deviated from the younger patients in 
both countries, but even though the gap narrowed with 
time, the oldest age group lagged behind; yet, the two 
oldest groups appeared to have the most favourable survival 
improvement.
Figure 2 Age- specific 1- year relative survival for rectal (and anal) cancer in (A) Finnish and (B) Swedish men and 5- year 
survival in the same male populations (C, D). For A and B, all data points for the youngest and oldest age groups are outside 
the 95% CI limits of all rectal cancer survival (cf. table 1); the exception is the Finnish youngest age group. For C and D, all data 
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The female results for survival in colon cancer are shown 
in figure 3. The differences between the age groups were 
very large for Finnish 1- year and 5- year survival (A and C), 
and the oldest age group was not able to catch up. While 
Swedish 1- year survival (B) deviated between the age groups, 
but 5- year survival rates were remarkably uniform from the 
1970s onward.
Age- specific 1- year relative survival for rectal (and anal) 
cancer in Finnish (figure 4A) and Swedish (figure 4B) 
women and 5 year survival in the same female populations 
(C and D) showed very large differences between the age 
groups and these remained to the end of follow- up.
DISCUSSION
Success in cancer control is measured by improvements in 
survival but a proper interpretation of survival data requires 
background data on incidence and mortality rates.1 The 
incidence rate of colon cancer in Finnish and Swedish men 
and women has continuously risen, and among Finns at a 
remarkable rate. The present ecological study is not able 
to point out the reasons for such increases but some risk 
factors of colon cancer may have become more prevalent, 
including increasing body weight, higher consumption of 
processed meat and lower consumption of whole grain and 
milk products.22 For rectal cancer, the increases in incidence 
rates were less than for colon cancer. Whatever the reasons 
might be, comparison of the survival rates between the 
periods assumes that the underlying disease is comparable. 
Practically all CRC samples have been histologically verified 
in the Finnish and the Swedish cancer registries but this is 
no guarantee against ‘stage migration’.16
In the early follow- up periods, 1- year survival in rectal 
cancer was better than for colon cancer but the gap narrowed 
with time; the results were consistent for men and women in 
both countries (online supplemental figures 2 and 3). The 
5- year survival curves for the two cancers were superimpos-
able. Both sets of plots were moderately curvilinear implying 
that the improvements in survival were larger in the early as 
compared with the late periods. This was also demonstrated 
in tables 1 and 2 as a larger number of statistically significant 
increases in CRC survival were observed between the early as 
compared with the late follow- up periods. These tables also 
showed that survival for no single cancer type was signifi-
cantly increased in the last period raising concerns that the 
positive development has slowed down or stalled.
The survival difference between years 1 and 5, shown in 
tables 1 and 2 and in online supplemental figure 4), conveys 
the message that 5- year survival increase in colon cancer 
was entirely covered by the improvement in 1- year survival, 
implying that care between years 1 and 5 was not able to 
save further lives. This may imply that surgery with adjuvant 
therapies has been able to contribute to 1- year survival but 
Figure 3 Age- specific 1- year relative survival for colon cancer in (A) Finnish and (B) Swedish women and 5- year survival in the 
same female populations (C, D). For A, B and C, all data points for the youngest and oldest age groups are outside the 95% CI 
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chemotherapy or other therapies for metastatic colon cancer 
have not improved 5- year survival beyond what is achieved 
with adjuvant therapy. This does not exclude the possibility 
that newer drug regimens improve survival at time points 
between 1 and 5 years, as demonstrated in clinical trials.23
For rectal cancer, the development was far more opti-
mistic; for Finland, there was a major improvement in 
survival after year 1, starting from the late 1980s, while in 
Sweden the trend started earlier but was weaker. Improve-
ments in surgical procedures, such as total mesorectal exci-
sion, and wide use of preoperative chemoradiotherapy have 
been associated with favourable survival in rectal cancer.24–27
The age- specific survival for colon cancer showed a posi-
tive development for all age groups, and the early lag for 
survival in the oldest age group almost disappeared towards 
the end of the follow- up period and practically disappeared 
in the 5- year survival. Curiously, Finnish patients with colon 
cancer below age 50 survived very well up to 5 years. Survival 
in rectal cancer showed large age group specific differences 
which narrowed over time but the oldest age group clearly 
lagged behind the others.
One interpretation of these data is that newer treatment 
regimens have their biggest impact when used as adjuvant 
therapies. Patients surviving 1 year include patients that were 
cured, and those that are alive with advanced disease, while 
5- year survival mostly indicates cure rates, as few patients 
with metastatic disease survive 5 years despite improvements 
in therapy. Therefore, comparing the difference between 
1- year and 5- year survival provides interesting insight into 
where newer therapies and earlier detection are most useful 
with regard to survival. In colon cancer, the difference 
between 1- year and 5- year survival has remained constant 
over decades, while in rectal cancer it has decreased, indi-
cating a relative increase in the proportion of patients 
cured. These findings are compatible with bigger improve-
ments in curative treatment in rectal versus colon cancer. 
One possible explanation is radiation therapy, which is used 
widely in rectal cancer, with or without concurrent chemo-
therapy, but not in colon cancer.
The strengths of the study are that we have data from two 
countries with practically free medical care offered to the 
population at large, covered by nationwide cancer registries 
of high quality. Such circumstances are commensurate with 
the concept of 'real world’ experience. The weaknesses are 
that the data are ecological and no individual level treat-
ment or care data were available. Lack of stage data in the 
Nordcan database does not allow inclusion of this variable 
which is an important predictor of survival.28 It is generally 
assumed that the Finnish and Swedish treatment guidelines 
for CRC are principally similar and largely follow the Euro-
pean guidelines.29 However, in the early period, Sweden 
probably adopted novel therapeutic introductions earlier 
than Finland. Finally, we are unable to know when and to 
what extent the therapeutic improvement penetrated the 
nationwide care practice, with the exception of the reports 
from the Swedish Colorectal Cancer Registry.30–32
Our results show, in agreement with a wealth of the 
global and local literature, that the relative survival in CRC 
Figure 4 Age- specific 1- year relative survival for rectal (and anal) cancer in (A) Finnish and (B) Swedish women and 5- year 
survival in the same female populations (C, D). For all panels, all data points for the youngest and oldest age groups are outside 
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has increased in Finland and in Sweden during the past 
50 years.6–8 14 33 Yet some caution is warranted about the 
magnitude because of the rising incidence trends. The 
steady increase in survival implies that the trend cannot be 
ascribed to any single major change in care but rather to 
multiple positive changes taking place over time. For colon 
cancer, the main improvement was in 1- year survival while 
the period from 1 to 5 years did not contribute, opposite 
to rectal cancer for which even the survival between years 
1 and 5 improved after around year 1980. Yet, in rectal 
cancer survival for the oldest patients lagged far behold the 
younger age groups. The analysis pointed out a concern that 
the overall positive development in survival has been most 
slow in the last period.
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